Background Hidradenitis suppurativa (HS) is a recalcitrant chronic skin disease with poorly understood immunopatho-
Introduction
Treatment of hidradenitis suppurativa (HS), also called acne inversa, a chronic inflammatory skin disease, is challenging and tedious because of the poorly understood pathogenesis. HS is painful and lowers the patient's quality of life considerably. 1 It manifests through subcutaneous nodules and deep dermal abscesses in axillary, inguinal and anogenital areas of the body and is accompanied by malodorous suppuration. 2 The initial starting point of HS is thought to be follicular keratinization leading to the occlusion, dilation and rupture of the pilosebaceous unit. This results in an infiltration of inflammatory cells into the dermis with a subsequent dysregulation of the immune system. 3, 4 The IL-36 cytokines (IL-36a, IL-36b, IL-36c and IL-36RA) are interleukins of the IL-1 cytokine family and are mainly produced by keratinocytes. 5 The three different agonistic isoforms of IL-36
(IL-36a, IL-36b, IL-36c) are proinflammatory and are induced by themselves 6, 7 as well as by other cytokines, such as IFN-c, IL1a, IL-1b, IL-17, IL-22, IL-23 and TNFa. 5, [8] [9] [10] IL-36a, IL-36b and IL-36c have similar functions. In more detail, IL-36a stimulates the production of IL-17 and IL-23. 8 The isoform IL-36b induces antimicrobial peptides, matrix metalloproteinases and IL-8 expression in keratinocytes. 9 IL-36c is induced in macrophages by mycobacterium tuberculosis, 11 and it upregulates not only chemokines (CXCL8, CCL2, CCL5 and CCL20) but also the adhesion molecules VCAM-1 and ICAM-1. . Serum was stored at À20°C. Study subjects were never treated with biologics or immunomodulatory drugs, and systemic antibiotics were stopped at least 3 weeks before skin biopsy or blood donation.
Material and Methods

Samples from patients
Immunohistochemical staining
Immunohistochemistry for IL-36a, IL-36b, IL-36c and IL-36RA (see list of primary antibodies in Table 1 ) was performed using the streptavidin-biotin complex/alkaline phosphatase method. 19 Briefly, FFPE tissue sections were deparaffinized, rehydrated and pretreated in citrate puffer (pH6) for either 10 min in the pressure cooker (IL-36b and IL-36c) or 5 min in the microwave (400 Watt) (IL-36RA). Sections for IL-36a were pretreated with TE-buffer (pH 9) for 10 min in the pressure cooker, and then all sections were rehydrated in 0.1% saponin containing Tris-buffered saline. After blocking (Roti-ImmunoBlock; Roth GmbH, Karlsruhe, Germany) for 15 min, sections were incubated with the primary antibody for 1 h at room temperature, followed for 1 h by a biotinylated rabbit anti-goat secondary antibody (E0466, Dako, Santa Clara, CA, USA), and thereafter, sections were treated with the streptavidin-biotin complex/alkaline phosphatase method (551008; BD Biosciences, San Diego, CA, USA). Finally, the sections were developed with the Fuchsin SubstrateChromogen System (KO625, Dako) and counterstained with haematoxylin for 3 min. To ensure specific detection, the same tissue was stained with the secondary antibody only. To quantify the expression of the IL-36 cytokines in the epidermis, a semiquantitative score was used. 33 In short, density and intensity of the staining as well as spread over the epidermis were assessed and included in the allocation of the score, which ranged from 0 (no expression) to 3 (very high expression).
RNA isolation and complementary DNA synthesis
As previously described, 19 around 1 mm of snap frozen tissue was cut into 10 lm sections and collected in a frozen tube. RNA was extracted by means of the RNeasy lipid tissue mini kit (Qiagen, Valencia, CA, USA). Possible contaminating DNA was removed with an RNase-free DNase step (Qiagen) following the manufacturer's protocol. A total of 500 ng of RNA was used to synthesize complementary DNA using the BD Reverse Transcriptase Kit (BD Bioscience) according to the manufacturer's indications.
Semiquantitative real-time PCR analysis
PCR primers and probes were purchased (Applied Biosystems, Foster City, CA, USA) as premade Taqman© gene expression assays. The following primer pairs, spanning exon-exon borders, were used: IL-36a (Hs00205367_m1), IL-36b (Hs00205359_m1), IL-36c (Hs00219742_m1) and IL-36RA (Hs01104220_g1); and the following two reference genes: b 2 -microglobulin (B2M) (Hs99999907_m1) and hypoxanthine phosphoribosyltransferase-1 (HPRT-1) (Hs99999909_m1). The semiquantitative real-time PCR was performed with ABI-Prism 7300 Sequence Detector System (Applied Biosystems) as previously described. 19 In short, for complementary DNA amplification, a 10 min incubation at 95°C was performed to activate AmpliTaqGold (Applied Biosystems), followed by 45 cycles with 15 s at 95°C and 1 min at 60°C. The results are expressed as fold difference. To determine these differences, relative units were calculated by the 2 ÀDDCT method: The threshold cycle (CT) for the target amplicon and the CT for the reference genes were determined for each sample. Differences in the CT of the target and the geometric mean of the CT of the two reference genes (see Ref. 34 ), called DCT, were calculated to normalize for the difference in the amount of total nucleic acid added to each reaction. The DCT of control skin (calibrator) was subtracted from the DCT of each sample and termed as DDCT. The amount of target normalized to the endogenous control and relative to the calibrator was then calculated by the equation 2
ÀDDCT
. In samples, where no CT value could be determined, the CT value was set as 42, as described in Ref. 35 
Enzyme-linked immunosorbent assay (ELISA)
To detect IL-36a, IL-36b and IL-36c in the serum, the antibodies and standards in Table 1 were used. IL-36RA was detected by (e-h) Quantification of the intensity and density of IHC stainings for the IL-36 cytokines. Score ranges from 0 to 3 in the three donor groups; n(healthy skin) = 6, n(HS) = 6, n(PS) = 6. Data are presented as mean with SEM and were statistically analysed with the Mann-Whitney test, with *indicating a P-value <0.05, **indicating a P-value <0.01, ***indicating a P-value <0.001. [Colour figure can be viewed at wileyonlinelibrary.com] the IL-36RA DuoSet ELISA kit (RnD Systems, Minneapolis, MN, USA, DY1275-05). All ELISAs were performed according to the manufacturer's instructions. The results are expressed either in ng/mL or in pg/mL.
Statistical analysis
Statistical analysis was performed with GraphPad Prism software, version 5.01 for Windows, San Diego, CA, USA. Quantification of IHC staining, semiquantitative real-time PCR and ELISA was analysed by means of the non-parametric MannWhitney test. A P-value lower than 0.05 was considered significant, with *P < 0.05, **P < 0.01 and ***P < 0.001.
Results
IL-36 cytokines are expressed in lesional HS skin
Analysis of protein expression of the IL-36 cytokines was performed by immunohistochemistry on FFPE tissue sections of lesional HS and PS skin as well as on healthy skin. Representative examples of all four stainings are shown in Fig. 1a-d , and analysis with a semiquantitative score of six sections per donor group is shown in Fig. 1e-h . As expected, lesional PS skin showed high epidermal protein expression of all IL-36 cytokines, while healthy skin expresses the IL-36 cytokines only minimally. Lesional HS skin shows a trend towards elevated protein expression of IL-36a (P-value = 0.26) and IL-36RA (P-value = 0.06) and a significant upregulation of IL-36b (P-value = 0.02) and IL-36c (P-value = 0.02), even though levels are not as high as in lesional PS skin.
IL-36a mRNA is significantly upregulated in lesional HS skin
After investigating IL-36 expression on the protein level, we analysed the mRNA levels of IL-36a, IL-36b, IL-36c and IL-36RA by semiquantitative RT-PCR. Relative changes in gene expression between lesional patient skin (HS and PS) and healthy skin are shown in Fig. 2a-d . In accordance with our IHC results and with the literature, all IL-36 cytokines are significantly elevated in lesional PS skin compared with healthy skin. In HS, only the agonistic isoform IL-36a shows a statistically significant increase (mean increase = 45.07, P-value = 0.01) in comparison with healthy skin, with both IL-36b (mean Ct-values were normalized with housekeeping genes HPRT-1 and B2M to healthy skin (=1); n(healthy skin) = 7, n(HS) = 25, and n(PS) = 6. Data are presented as mean with SEM and were statistically analysed with the Mann-Whitney test, with *indicating a P-value <0.05, **indicating a P-value <0.01, and ***indicating a P-value <0.001. Systemic levels of agonistic IL-36 cytokines trend to be elevated in patients with HS
To investigate whether systemic levels of the IL-36 cytokines correlate with lesional expression in HS patients, sandwich ELISA was performed with serum from the three donor groups (healthy donors and HS and PS patients) (see Fig. 3a-d) . In healthy donors, no or only low concentrations of the IL-36 cytokines could be detected, while patients with HS show a trend towards elevated levels of isoforms IL-36a (P-value = 0.16), IL-36b (Pvalue = 0.31) and IL-36c (P-value = 0.12) with no detection of the IL-36RA. Patients with PS have high IL-36 cytokine levels in their serum, even though no statistical significant differences could be detected.
Discussion
We show that IL-36a, IL-36b and IL-36c are significantly upregulated locally (on the mRNA or the protein level) and also show a tendency towards a systemic upregulation in patients suffering from the recalcitrant skin disease HS, while the IL-36RA is neither significantly elevated on the protein and mRNA level nor on the systemic level. Furthermore, we found high local and systemic levels of all IL-36 cytokines in psoriatic skin.
IL-36 cytokine expression in lesional HS skin was found to be elevated compared to healthy skin but lower than in lesional PS skin, which suggests different pathogenetic events in those two chronic inflammatory skin diseases. This is especially remarkable as previous studies could not find any striking differences between these two conditions when analysing the expression of various cytokines and antimicrobial peptides. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] One of the reasons for the lower IL-36 levels in HS compared with PS could be that HS is not a disease of the epidermis but rather of the hair follicle, and inflammation is mostly present in the dermis. Even though hyperkeratinization can be detected in HS, 36 this effect is much more pronounced in PS, and as keratinocytes are the major producers of IL-36, this could explain why we see lower levels in HS than in PS. Additionally, the importance of other members of the IL-1 cytokine family in HS pathogenesis is controversial. In vivo evidence with blockade of IL-1b in HS patients yielded conflicting results. [37] [38] [39] Interestingly, when Boutet et al. 40 compared mouse models of psoriasis, rheumatoid arthritis and Crohn's disease, IL-36 levels were elevated in all the models, but in the psoriasis model they were the highest. Still, it is difficult to speculate about the relevance of IL-36 in HS pathogenesis and how HS immunopathogenesis differs from that of PS. What we can show with our data is that in HS the IL-36 cytokines are upregulated, which fits well with the reported Th1/Th17 phenotype present in lesional HS skin. 19, 41 Dysregulated IL-36 levels have also been implicated in other inflammatory diseases. Levels of the IL-36 cytokines have been reported to be comparable to healthy skin in atopic dermatitis, lichen planus, subacute cutaneous lupus erythematosus and mycosis fungoides 42 and high in allergic contact dermatitis. 43 Moreover, IL-36 was shown to be an important cytokine for mucosal immunity. 44 In a mouse model for Crohn's disease, IL-36 was upregulated in the intestinal inflammation, and IL36R-/-mice show reduced mucosal inflammation. 45 In humans, two recent studies analysing IL-36 in patients with inflammatory bowels disease (IBD), and in particular ulcerative colitis, showed increased local expression of IL-36. 45, 46 This shared upregulation of the IL-36 cytokines would suggest that common pathomechanisms exist in the development of HS and IBD, which may at least in part explain the reported association between the two inflammatory conditions. 47 Taken together, the agonistic isoforms IL-36a, IL-36b and IL-36c are upregulated in lesional HS skin, while IL-36RA does not seem to be upregulated. Future studies are required to determine the cellular and cytokinic background of HS pathogenesis and to clarify the exact role of IL-36 in this process.
